Journal
AIDS
Volume 31, Issue 15, Pages 2035-2052Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAD.0000000000001574
Keywords
antiretroviral therapy; antiviral therapy; liver/hepatitis; pathogenesis; reverse transcriptase inhibitors
Categories
Funding
- National Health and Medical Research Council of Australia (NHMRC) [1101836, 1024406]
- NHMRC Practitioner Research Fellowship [1042654]
- United States National Institutes of Health [U19 AI096109]
- NHMRC [1039055]
- National Health and Medical Research Council of Australia [1101836] Funding Source: NHMRC
Ask authors/readers for more resources
HIV infection has a significant impact on the natural history of chronic hepatitis B virus (HBV) infection, with increased levels of HBV DNA, accelerated progression of liver disease and increased liver-associated mortality compared with HBV monoinfection. Widespread uptake and early initiation of HBV-active antiretroviral therapy has substantially improved the natural history of HIV-HBV coinfection but the prevalence of liver disease remains elevated in this population. In this paper, we review recent studies examining the natural history and pathogenesis of liver disease and seroconversion in HIV-HBV coinfection in the era of HBV-active antiretroviral therapy and the effects of HIV directly on liver disease. We also review novel therapeutics for the management of HBV with a particular emphasis on clinical strategies being developed for an HBV cure and an HIV cure and their impact on HIV-HBV coinfected individuals. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available